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BET BROMODOMAIN PROTEINS CONTROL BREAST CANCER 
AGGRESSIVENESS PROMOTED BY ADIPOCYTE-DERIVED EXOSOMES 
THANG HOANG 
ABSTRACT 
 Cells can release lipid bilayer vesicles of endosomal and plasma membrane 
origin, which are known as exosomes or extracellular vesicles (EVs). EVs contain diverse 
shuttling lipids, RNA and transmembrane proteins, and play an important role in 
communicating between neighboring or distant cells. Breast cancer is the most commonly 
diagnosed malignancy, with over 2 million new cases in 2018, and is the leading cause of 
cancer mortality in women all over the world. Some observational studies have suggested 
that breast cancer is more likely to develop among women who have type 2 diabetes; the 
association is clear in postmenopausal women. Moreover, women with type 2 diabetes 
diagnosed before, at the same time, or after breast cancer diagnosis, have decreased 
overall survival compared to women without diabetes.  
 The most recent medical studies provide more clues as to why breast cancer is 
more common and has poorer prognosis in type 2 diabetes patients, by pointing out the 
role of insulin-resistant adipocytes in the etiopathology. Here, we demonstrate how 
insulin-resistant adipocytes engage crosstalk with breast cancer cells through EVs in the 
microenvironment and drive the tumor cells to be more metastatic and aggressive. These 
progression mechanisms and the effects of insulin-resistant adipocytes on breast cancer 
cells require Bromodomain and ExtraTerminal (BET) proteins – an important epigenetic 
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pathway. Targeting this pathway may help reduce morbidity and mortality of women 
with breast cancer and type 2 diabetes.  
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 Breast cancer is the most com monly diagnosed malignancy among women in the 
high socioeconomic countries (1). Worldwide, breast cancer impacts 2.1 million women 
each year and also causes 627,000 deaths, which accounted for 15% of all cancer-related 
death among women in 2018 (2). According to recent reports, the number of worldwide 
reported breast cancer cases intensively increased approximately 20% since 2008 (2,3).  
The global incidence of breast cancer has been increasing by about 3.1% each year, from 
641,000 cases diagnosed in 1980 to over 2.1 million in 2018 (4). It is estimated that 
approximately one new case was diagnosed every 18 seconds in 2018 (4,5). About 
250,000 new cases of invasive breast cancer are expected to be diagnosed each year in 
the U.S. Approximately 13% (1 in 8) of women will be diagnosed with invasive breast 
cancer in their lifetime and about 42,170 women will die from breast cancer in 2020 (6). 
Therefore, invasive breast cancer is a major public health problem of deepening 
seriousness worldwide. 
Indeed, the breast cancer burden is increasing in developed countries as well as 
developing countries, regardless of epidemiological characteristics such as income, high 
population growth or aging of the population. Although the incidence of female breast 
cancer death significantly declined from the peak at 33.2 (per 100,000) in 1989 to 19.8 in 
2017 because of early detection with mammography and efficient adjuvant therapy (7,8), 
there are still many problems in treating this disease and decreasing the mortality rate. 
Menopausal hormone therapy, alcohol consumption and physical inactivity are 
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potentially associated with higher incidence of breast cancer, while being 
overweight/obesity is associated with worse prognosis of postmenopausal breast cancer 
(9). In addition, there are a variety of non-modifiable risk factors that include the 
mutation of breast cancer susceptibility genes (BRCA1, and BRCA2) and a personal or 
family history of breast or ovarian cancer (10,11).  
Breast cancer epidemiology and prognosis vary among different races and groups 
of age. In the U.S., incidence rates are higher among Non-Hispanic (NH) black women 
before age 40 and survival rates are lower, compared to NH white women (12). At the 
time of diagnosis, about 64% of patients are diagnosed with local-stage breast cancer, 
27% with the regional metastasis, and 6% of breast cancer patients have distant 
metastasis. Five-year relative survival rates for metastatic breast cancer are 
approximately 27%. Stage at the time the patients are diagnosed, as well as breast cancer 
incidence rates and mortality rates, vary by ethnicity (NH Black, NH White, 
Asian/Pacific Islander, Hispanic/Latina, and American Indian/Alaska Native) (13,14).  
Breast cancer is a group of diseases in which cells in the breast proliferate in an 
uncontrollably. Breast cancer can emerge from different parts of the breast such as 
lobules where milk is produced, ducts which collect the milk and work as a system to 
bring milk to the nipple, and connective tissue, which includes fibrous and fatty types of 
connective tissue. On the histological and molecular level, breast cancer is also a 
heterogeneous disease, defined by diverse features of the malignancy cell of origin and 
molecular features which include expression of human epidermal growth factor receptor 
2 (HER2), hormone receptors such as estrogen receptor (ER) and progesterone receptor 
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(PR) and mutations in specific genes (15). Hence, treatment decisions differ according to 
these histological and molecular characteristics. In spite of our remarkable understanding 
about the molecular features and pathology of breast cancer, the disease remains a 
massive public health burden where advanced breast cancer is generally considered 
incurable (16). The mortality rates vary among the subtypes of breast cancer, with the 
highest rate (among women ≥65 years of age) in non-luminal HER2-positive disease 
[Hazard Ratio (HR) 2.21 (95% confidence interval (CI) (1.62-3.01)], then luminal B [HR, 
1.69; 95% CI, 1.28-2.24], luminal A [HR, 1.51; 95% CI, 1.33-1.71] and triple negative 
breast cancer [HR, 1.25; 95% CI, 1.03-1.53]. Mortality rates also vary by ethnicity and 
age (17). These patterns suggest that personalized therapy will be critical and prioritized 
in breast cancer research for the development of novel strategies to optimize the efficacy 
and tolerance of recent therapies.  
Although a high stress lifestyle and high alcohol consumption play roles in 
increased incidence risk, obesity is also becoming a crucial risk factor, as well as one of 
the poor prognostic factors among metastatic breast cancer survivors (19). During the last 
two decades, the number of overweight and obese individuals has steadily increased (20). 
Besides older age and being female, being overweight or obese is also well established to 
be associated with increased risk of developing breast malignancy in postmenopausal 
women (21). Conversely, in premenopausal women, obesity is associated with decreased 
breast cancer incidence (22), but poorer prognosis. Moreover, obesity is independently 
associated with overall poorer prognosis of breast cancer (22,23). Women who are 
physically inactive, have diabetes or have insulin resistance syndromes are more likely to 
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have breast cancer (24). Significant evidence demonstrates that obesity increases the risk 
of recurrence or death by 25% to 50%, which is independent of hormone receptor status 
(25). Moreover, obesity also causes insulin resistance that promotes hyperinsulinemia and 
impaired glucose tolerance (26,27). Insulin resistance is related to poor survival in all 
breast cancer subtypes (28). Not only hyperinsulinemia and impaired glucose tolerance 
are extensively reported to directly associate with tumor growth and metastasis, but also 
emerging evidence demonstrates that insulin resistance status clearly drives the epithelial-
mesenchymal transition (EMT) of breast cancer through crosstalk between EVs of 
adipocytes and cancer cells in the tumor microenvironment (29,30). EMT is a process 
that allows cells to lose their epithelial characteristics by depolarizing and reducing their 
cell-cell connections. As EMT occurs, cells become more mesenchymal and gain 
migratory and invasive capacity (31). A recent observation has shown that metformin, a 
medicine that lowers insulin level and increases insulin sensitivity and is a first line drug 
for type 2 diabetes (T2D), has a potential anti-cancer effect by reducing proliferation and 
migration capacity through activation of adenosine monophosphate-activated protein 
kinase (AMPK) (32). Because of the complexity of insulin resistance caused by 
inflammation, restricted oxygen intake and/or higher level of insulin, additional research 
about insulin resistance linked to breast cancer is needed to improve our understanding in 
order to develop tailored treatment for pre-diabetes and type 2 diabetes patients 
diagnosed with breast cancer (33). 
Tumor microenvironment (TME) has been universally recognized as a substantial 
contributor to tumor progression. Evasion, invasion and metastasis, evading apoptosis, 
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inducing angiogenesis and therapy resistance are tightly connected to TME, which 
includes a variety of cell types, extracellular matrix (ECM), secreted proteins, and small 
molecules (34). In the last decades, there is a significant growing interest in nano-sized 
vesicles such as EVs and their roles in TME. Emerging data suggest that EVs shuttle 
many physiological and pathological biomolecules to play a role in intercellular 
communication (35). EVs are nanoparticles, phospholipid bilayer membrane organelles 
that are created by budding of plasma and endosome membranes (35,36). EVs are 
released from a variety of cells, prokaryotes and eukaryotes, to communicate with targets 
or distant cells by the fusion with plasma membrane of the recipient cells. EVs can be 
categorized in two groups, ectosomes and exosomes (37) (Table 1). Because of its 
distinctive subset of cargo and smaller size vesicle, there has been growing interest in 
exosome research in the last decade. In the 1990s, the mechanism of exosome release was 
found in B lymphocytes and dendritic cells in the same way as multivesicular bodies 
(MVBs) fuse with plasma membranes (38). The early definition of exosomes is 
considered to be secreted vesicles that are functional in physiology (39). Many more 
forms of evidence demonstrate that the role of MVBs in releasing the exosomes is crucial 
in both hematopoietic and non-hematopoietic cells, such as cytotoxic T cells, neurons, 
and intestinal epithelial cells (40). Furthermore, the physiological function of exosomes 
and their secretion were reported as general and basic cellular functions in a variety of 
cells. Exosomes are the lipid bilayer vesicles in the size of ~40 to 160 nm (average ~100 
nm) in diameter, containing transmembrane proteins, DNA, RNA, lipids and metabolites 
(41). Exosomes bring their contents, such as nucleic acids, metabolites, and proteins from 
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the origin cells to the recipient cells to effectively change the target cells’ biological and 
morphological characteristics (42,43,44,45). The emerging data also suggest that 
exosomes play an important role in not only intracellular communication in the TME but 
also in disease diagnosis by characterization of their cargoes. 
 
Table 1. Extracellular vesicles’ characteristics. 
 
Characteristic Exosomes Ectosomes 
Properties  ~40-160nm ~100-1000nm 
Origin Intracellular multivesicular 
bodies (MVBs)  
Plasma membrane 
Characteristic  Homogeneous Heterogenerous  
Content DNA, RNA, lipids, cytosolic 
and cell-surface proteins and 
metabolites, amino acids 
Proteins, mRNAs, miRNAs 
Common markers CD9, CD81, CD63, ALIX, 
TSG101, flotillin, ceramide 
TyA, C1q 
 
 In order to investigate the aggressive behavior of breast cancer cells in breast 
cancer patients, we profiled EMT characteristics of breast cancer cells. EMT is a biologic 
and pathological program that facilitates acquisition of the potential of migrating, 
increased cancer stem-like cell formation and transcriptional plasticity in cancer cells 
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(46). When the EMT process is activated, it allows multiple biochemical changes of the 
polarized epithelial cell that increase aggressiveness, migratory capacity, and 
chemotherapy resistance (47). Tumor cells start losing their epithelial markers such as E-
cadherin, epithelial cell adhesion molecule (EpCAM), as well as their polarized epithelial 
features (48). The cells begin to detach from the basement membrane and acquire a 
mesenchymal state by gaining more mesenchymal markers such as vimentin and alpha-
smooth muscle actin (alpha-SMA) (49). In the progress of EMT, TME and intercellular 
communication synergize to direct the cells and enhance their invasive capacity to the 
metastatic sites. By the end of the EMT program, tumor cells will have lost many of their 
epithelial markers and will express many mesenchymal markers (50) (Fig. 1). Upon 
metastasis and arrival at the targeting sites, cancer cells reverse EMT by inducing a MET 
program to adhere and form metastatic tumors in specific organs (51). Expression of 
EMT markers associates with poor prognosis and reduced overall survival rate in ovarian 
cancer, breast cancer and other tumor types (52). EMT will lead to the dissemination of 
cancer cells and become more invasive in circulating tumor cells (CTCs) (53). Recent 
studies demonstrate that EMT enhances the expression of important mesenchymal genes 
such as Vimentin, its transcription factor ZEB1, Snail, Slug, MMP2, and Twist1 to 
change the skeletal systems to mobilize the cells (54,55). Moreover, after EMT, the 
tumor cells not only become more plastic but also therapy resistant by expressing cancer 
stem cells markers (56). The theory “seed and soil” highlighted by Paget (1889) 
suggested the important role of dynamic interaction between the cancer cells and TME 
around the tumor to support the proliferation and invasion of cancer cells (57,58). The 
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emerging data have shown the role of exosomes in the TME, which may induce EMT and 
transfer the crosstalk signals between the cancer cells and the host microenvironment. 
 
Figure 1. Epithelial-mesenchymal transition  
 Due to the critical role of Bromodomain and ExtraTerminal domain proteins 
(BET proteins) in regulating breast cancer metastasis by interacting with metabolic 
pathways and and the EMT program, much research has focused on the beneficial effects 
of BET inhibitors on treating a variety of cancer (59) in recent years. Bromodomain and 
ExtraTerminal domain proteins are a family of proteins that include BRD2, BRD3, BRD4 
and germ-cell-specific BRDT (60). BET proteins play an important role in regulating 
gene transcription by specific binding to acetylated lysine residues in nucleosomal 
histones as an epigenetic factor (61,62). BET proteins have been established to be 




Expressing more mesenchymal markers (e.g. 




significantly involved in malignancies such as prostate, lung, pancreatic and breast 
cancer, hence, intense awareness of the possibility of developing multiple BET protein 
inhibitors is an exciting new way to target particular malignant diseases (63,64,65). 
Recently, a number of research reports have investigated the ability of JQ1- a pan-BET 
inhibitor- to reduce the aggressiveness and metastatic capacity of breast cancer (66). 
However, the wide range of expression and function of each particular BET protein 
shows that specific BET inhibitors are needed. Recent data also show that a specific 
target BET inhibitor, MZ1, can modulate the signaling pathway of BRD4 proteins and 
tumor growth and invasive ability of tumor cells.  
Here, we demonstrate how BET proteins regulate breast cancer aggressiveness 
promoted by insulin-resistant adipocyte-derived exosomes and highlight the effect of 







MATERIALS AND METHODS 
 
Cell Culture 
The 4T1 cell line is a transplantable, highly tumorigenic and invasive breast 
cancer cell line that works well as an experimental animal model for human breast 
cancer. When transplanted into the BALB/c strain of mice, the 4T1 cell line 
spontaneously establishes a highly aggressive tumor that can metastasize to distant 
organs such as lymph node, lung, liver and brain. 4T1 cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum 
(FBS) and 1% antibiotic-antimycotic (penicillin/streptomycin [P/S], Gibco). The cells 
were grown and maintained in 10 cm2 tissue culture dishes in a humidified atmosphere in 
37oC and 5% CO2 incubator.  
Swiss 3T3-L1 fibroblasts were cultured in 10 cm2 dishes until the cells reached 
confluence, then were kept over-confluent for 48 hours before they were differentiated 
for another 48 hours with DMEM supplemented with 1 µM dexamethasone, 0.5 mM 
isobutylmethyl xanthine (IBMX), 1.67 µM insulin, and 10% FBS (67). Subsequently, the 
cells were washed with phosphate buffered saline (PBS) without CaCl2 and MgCl2, and 
maintained in DMEM media supplemented with for 1.67 µM insulin and 10% FBS. Next, 
the cells were divided into two groups to be the insulin-sensitive (IS) and insulin-resistant 
(IR) adipocytes. We created IR adipocytes by treating 3T3-L1 adipocytes overnight with 






IS adipocytes and IR adipocytes were washed with PBS and kept in normal 
DMEM for 72 hours to allow the cells to secrete exosomes into the media (conditioned 
media). IS and IR adipocyte conditioned media were collected in Falcon 50ml Conical 
Centrifuge Tubes and centrifuged at 2,000g for 30 minutes at 4oC to remove cells and 
debris. Total exosome isolation reagent (Invitrogen, US) was added into the cell-free 
conditioned media and mixed well. The samples were incubated at 4oC overnight and 
were centrifuged at 10,000g for 1 hour at 4oC. The pellets were resuspended in 500µL of 
PBS. Exosomes were quantified using NanoSight NS300 system and 4T1 cells were 
exposed to the same amount of exosomes. 
qRT-PCR 
 Total RNA was extracted from 4T1 cells by using RNAeasy Kit (Qiagen). RNA 
integrity was assessed by Nano-drop. Reverse transcription reaction to generate cDNA 
was established with 1µg of total RNA with the QuantiTect® Reverse Transcription Kit 
(Quiagen). Complementary DNA was amplified using Tag-man PCR Master Mix on an 
Applied Biosystems (ABI) 7500 Fast Real-Time PCR Systems. The following gene-
specific primers from Thermo Fisher were assessed: Vimentin (Mm01333430_m1), 
TWIST1 (Mm00442036_m1), SNAI1 (Mm00441533_g1), E-CAD (Mm01247357_m1), 
β-ACTIN (Mm02619580_g1), ZEB1 (Mm00495564_m1), TJP1 (Mm00493699_m1).  
Immunoblotting 
Cells were harvested from 10 cm2 dishes and lysed in Radioimmunoprecipitation 
assay (RIPA) buffer (50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 150 mM 
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NaCl, 0.1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100). Sample protein 
concentrations were calculated by Bradford protein assay (68). Samples containing 20 µg 
of protein were loaded in 10 sample wells, separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose 
membranes. Membranes were blocked in Tris-buffered saline, 0.1% Tween 20 (TBST) 
containing 5% saturated milk protein to prevent non-specific binding of antibodies. 
Membranes were incubated with specific primary antibodies in 4oC overnight, washed 
with TBST and further incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies for 1 hour. The membranes were washed with TBST and  
subsequently exposed in Enhanced chemiluminescent reagent (ECL) for 1 minute. 
Proteins were visualized with BioRad ChemiDocTM XRS+ Imaging System. The images 
were analyzed and quantified by ImageJ software (69).  
The specific antibodies used were: anti-β-Actin as a housekeeping protein, anti-
Vimentin, anti-E-cadherin, anti-TWIST1 (Cell Signaling), anti-BRD2, BRD3, and BRD4 
from Bethyl Laboratories. Goat Anti-Mouse and Anti-Rabbit HRP-conjugated secondary 
antibodies were purchased from Biorad.  
Transwell Migration assay 
 The migration assay was established with 8-µm-pore size Transwell migration 
inserts (Costar). 4T1 cells were exposed to insulin-sensitive exosomes, insulin-resistant 
exosomes, and regular media exosomes as control for 3 days. Next, the cells were serum 
starved for 3 hours. 4T1 cells were then harvested, counted, and seeded at 7.5 x 104 
cells/well in the Transwell insert in 300 µL serum free DMEM. For migration assay, the 
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lower chamber was filled with 500 µL DMEM supplemented 10% FBS and 1% P/S 
(penicillin and streptomycin). Cell migration was allowed to progress for 10 hours at 
37oC, 5% CO2 in a standard incubator. At the end of this time, all cells on the upper 
surface of the insert were wiped away with a cotton swab, and cells on the lower surface 
were fixed and stained with methanol for 10 minutes and crystal violet for 5 minutes, 
respectively. To test the effects of BET protein inhibition MZ1, a BRD4 targetted 
inhibitor was used at concentration ranging from 25-100 nM. Images were taken by 
EVOS XL Core Imaging System (AMEX-100) and analyzed by ImageJ migration assay 
macro. All the migration assays were repeated three times. MZ1 was purchased from 
Tocris. 
Immunofluorescence 
Cells were fixed in methanol for 5 minutes at -20oC and permeabilized with PBS 
supplemented with 0.2% Triton X-100 buffer for 10 minutes. Permeabilized cells were 
incubated with blocking buffer (PBS supplemented with 0.02% Triton X-100 and 2% 
bovine serum albumin (BSA)) for 30 minutes to saturate all the non-specific protein-
protein binding sites. Sequentially, the cells were incubated with primary antibodies for 
30 minutes and then fluorochrome-conjugated secondary antibodies for 1 hour.  
List of antibodies are as follows: anti-Vimentin (rabbit mAb, Abcam; 1:1,1000), 
anti-E-cadherin (mouse mAb, Abcam; 1:1,000), Goat anti-Mouse IgG Secondary 
antibody Alexa Fluor 647 (Invitrogen, US; 1:1,1000), Goat anti-Rabbit IgG Secondary 
antibody Alexa Fluor 594 (Invitrogen, US; 1:1,1000), Phalloidin –iFluor 488 (Abcam: 




  The experiments were statistically analyzed by using Student’s t-test and ANOVA 
in Excel 2010 and GraphPad Prism8. Graphs were displayed by GrahphPad Prism8, and 






Adipocyte-derived exosomes regulate EMT in breast cancer cells 
In type 2 diabetes (T2D), insulin resistance and dysfunction of pancreatic β-cells 
have been widely demonstrated. Adipose tissue plays central roles in the transition from 
glucose intolerance to T2D. Recent data suggest that crosstalk between adipocytes and 
breast cancer by exosomes influences characteristics of breast cancer cells. However, the 
impact of insulin-resistant adipocytes has not been well established. This study focuses 
on inter-organ communication by exosomes between adipose tissue and breast tumor to 
test the hypothesis that metabolic dysfunction of adipocytes will also indirectly impact 
breast cancer cells.  
3T3-L1 Swiss pre-adipocytes were differentiated and stained with oil red O to 
image triglyceride containing lipid droplets (Fig. 2 A and B). Differentiated adipocytes 
were divided into two groups, which were either treated or not with 1 nM TNF-α. Non 
treated cells were Insulin-sensitive (IS) and TNF treated cells were insulin-resistant (IR). 
Exosomes from IS and IR 3T3-L1 adipocytes were isolated from media incubated with 
cells for 72 hours after TNF removal. IS adipocyte exosomes and IR adipocyte exosomes 
were quantified using a NanoSight NS300 system (Fig. 2C). 
 IS and IR adipocyte exosomes were then added to 4T1 breast cancer cell cultures 
in order to measure the response of these target cells. We found that the IR exosomes 
significantly increased EMT gene expression in 4T1 breast cancer cells. We assayed 
mRNA levels of the epithelial marker E-Cadherin (Fig. 3A), as well as mesenchymal 
markers TWIST1 and Vimentin (Fig. 3B) in the 4T1 control group, 4T1 treated with IS 
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exosomes and 4T1 treated with IR exosomes. We observed a significant increase of 
mesenchymal markers (TWIST1, Vimentin) in the IR exosome-treated group compared 
with IS exosome-treated group and control. Changes in mRNA levels between the three 
groups were matched by protein expression using actin as a loading control (Fig. 3C).  
Our interpretation is that the exosomal cargo will be different depending on the insulin 
sensitivity of the adipocytes that produced the exosomes.  
Emerging data by Dr. Naser Jafari suggest that human adipocyte-derived 
exosomes bring cartilage oligomeric matrix protein (COMP) to MCF7 human breast 
cancer cells to drive EMT in the targeted breast cancer cells. Proteomic analyses have 
revealed that insulin-resistant exosomes contain differentially elevated amounts of 
several proteins, the highest of which was COMP (also called TSP-5) in the payload of 
IR adipocytes. COMP provided by the exosomes promoted the EMT program in the 
targeted breast cancer cells. To test the hypothesis that COMP was the critically active 
factor for EMT function, we overexpressed recombinant COMP/TSP-5 in 4T1 cells using 
an expression vector and transfection with lentivirus. We observed that the transfected 
4T1 cells had EMT gene expression that was significantly increased compared to 4T1 
cells transfected with a vector encoding a scrambled sequence (Fig.4).  
We considered that COMP is just one of several possible factors produced by 
exosomes that potentially caused the crucial effects on the breast cancer cells. The 
adipocyte-derived exosomes should be carefully analyzed for all their other contents, 








   
(C) Insulin-sensitive exosomes: 
   
(D) Insulin-resistant exosomes: 
Figure 2. 3T3-L1 adipocytes: light microscopy before staining with Oil Red O, 40X 
 (A), after Oil Red O staining, light microscopy, 40X (B). Adipocyte-derived 
exosomes tracking analysis using NanoSight NS300 system. Insulin-resistant and 





   




                                                                                                
                                                                                                          
                       
 
(C) E-cadherin, Vimentin expression 
Figure 3. Adipocyte-derived exosomes induce markers of EMT in 4T1 cells. 
Epithelial markers, EpCAM (A), and EMT markers Vimentin, Twist1 (B) were 
determined by quantitative reverse transcription polymerase chain reaction with 
specific primers and beta-actin as house-keeping genes. E-cadherin and Vimentin 
were confirmed by immunoblot with actin as loading control (C). Mean ± SEM from 








n=3 independent experiments performed in triplicates. *p<0.05, **p<0.01, 
***p<0.001. 
 
(A) COMP expression 
 
(B) E-cadherin expression 
 
(C) Snai1, Vimentin, Twist1 expression 
Figure 4. Overexpression of COMP induces EMT in 4T1 cells. COMP was 
overexpressed in 4T1 cells using lentiviral transfection. Epithelial markers, E-
cadherin (B), and EMT markers Snai1, Vimentin, Twist1 (C) were determined by 
quantitative reverse transcription polymerase chain reaction with specific primers 
and beta-actin as housekeeping genes. Mean ± SEM from n=3 independent 




Mesenchymal transition of 4T1 breast cancer cells correlates with increased 
migration 
 Exosomes containing RNAs, DNAs, metabolites and proteins regulated EMT in 
breast cancer cells. The cargoes of the exosomes are transmitted to the recipient cells to 
regulate the protein transcription and drive the EMT program of the targeted cancer cells. 
In addition to upregulation of EMT genes as measured by RT-PCR, we confirmed that 
functional changes also resulted from delivery of the exosome payload. 
In order to understand the functional changes of 4T1 cells, which were exposed to 
IS exosomes and IR exosomes, we performed functional migration assays to demonstrate 
migration changes consistent with the EMT program and increased invasive/migratory 
behavior of the treated 4T1 cancer cells. We assayed 4T1 cell migration in a Transwell 
migration assay. 4T1 cells that were treated with insulin-resistant exosomes displayed the 
highest migratory capacity, compared to 4T1 cells treated with insulin-sensitive 
exosomes (which displayed an intermediate capacity) and compared to control (untreated 
4T1 cells), which were the reference for the assay (Fig. 5). Hence, EMT observed in 4T1 
cells induced by crosstalk between exosomes (IS and IR) and the cells themselves, and 
serves as a model for the TME of insulin resistant compared to insulin sensitive breast 




Control        IS         IR 
 
Figure 5. Adipocyte-derived exosomes increase migratory capacity of 4T1 cells. The 
migratory capacity of 4T1 cells was assessed by Transwell migration assay. Mean ± 
SD, with n=3 independent experiments established in triplicates. 
 
Adipocyte-derived exosomes alter 4T1 breast cancer cell morphology 
 The morphology of 4T1 cells that internalized IR exosomes showed more 
mesenchymal characteristics, hence, they considerably differed from control and 4T1 
cells treated with IS exosomes. Immunofluorescence (IF) staining showed that 4T1 cells 
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treated with insulin-resistant exosomes expressed the highest invasive capacity by 
expressing lower levels of the epithelial marker E-Cadherin and higher levels of 
mesenchymal marker Vimentin (Fig. 6). These experiments were conducted in 
collaboration with Dr Naser Jafari, a postdoctoral fellow in the lab. The fluorescence 
images confirmed immunoblot results of higher Vimentin levels in breast cancer cells 
treated with IR exosomes (Fig. 3C). 
 
Figure 6. EMT in 4T1 cells after 72 hours on IS, IR exosomes exposure. 
Immunofluorescence staining of Vimentin, E-cadherin, DAPI and phalloidin was 
performed on 4T1 cells in control, IS exosomes and IR exosomes treated groups. 
Multiple immunofluorescence staining of EMT markers for Vimentin (red), E-







BET protein inhibitor can downregulate aggressiveness and invasiveness of the 
breast cancer cells triggered by adipocyte-derived exosomes 
 In order to explore how BET proteins regulate aggressiveness of 4T1 breast 
cancer cells, we assessed BET protein expression in 4T1 cells treated with IS and IR 
exosomes. Brd2 and Brd4 protein expression increased in 4T1 cells treated with IS and 
IR exosomes (Fig. 7A). The effect of IR exosomes on 4T1 cells is more remarkable 
compared with IS exosomes. Based on the significant increase of BET protein expression 
in 4T1 cells treated with exosomes, we tried to decrease the aggressiveness of 4T1 cells 
by inhibiting BET proteins by MZ1, a BRD4 specific inhibitor. We treated 4T1 cells with 
different doses of MZ1 (25nM, 50nM, and 100nM) for 72 hours to find out the optimal 
dose to specifically degrade BRD4 over BRD2. 4T1 cells were treated with IR exosomes, 
or co-treated with IR exosome and MZ1 50nM for 72 hours to conduct migration assay. 
The observation suggests that inhibition of BRD4 reduced migration and invasion 
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     Control                         IR                    IR+MZ1 50nM 
C. Migration assay 
Figure 7. BET protein inhibition decreases migratory capacity of 4T1 cells 
stimulated by IR adipocyte-derived exosomes. BET proteins expression in 4T1 cells 
treated with IS and IR exosomes (A). MZ1 treatment with different doses to test its 
effect on BET protein expression in specific concentration, MZ1 50nM selectively 
degrades BRD4 over BRD2 and BRD3 (B). The invasion capacity of 4T1 cells was 
detected by Transwell migration assay. The area of cells adhered on the bottom of 
the inserts was quantified and depicted as a chart graph with n=3 independent 





 Breast cancer has become an increasingly serious burden worldwide in terms of 
the number of new cases; approximately 2.1 million cases were reported in 2018. A 
number of complicated factors underlie the origins of the disease, such as lifestyle, 
environment, and comorbidity, which require more in depth understanding about risk 
factors, molecular and histological features of disease and their impacts on the progress 
of disease. Whereas the obesity epidemic has become a heavy burden in the developed 
country, obesity and its link with breast cancer have been studied with concern, in order 
to reduce the burden of both diseases and generally improve the outcome of patients who 
acquire both diseases. Obesity is universally associated with insulin resistance syndrome 
in type 2 diabetes. Excessive secretion of a variety of factors, such as fatty acids, 
cytokines, and many hormones, is related to the development of insulin resistance. 
However, the exact mechanism of this scenario is still not clear. Emerging studies show 
that exosomes may play an important role in various metabolic complications by the 
transportation of abnormal cargoes to specific cells. Results suggest that exosomes may 
be one of the key modulators in the TME.  
 In this thesis, we discovered that adipocyte-derived exosomes induce EMT in 4T1 
cells, especially 4T1 cells treated with IR exosomes, which show about a 20-fold increase 
in Vimentin expression (Fig. 3). A potential role in EMT induction is suggested as 
COMP/TSP5, which is one of the diverse adipocyte-derived cargo was increased (Fig. 4). 
The induction of EMT changes 4T1 cells morphology to become more spindle-like cells 
and makes them more migratory and invasive (Fig. 5 and Fig. 6). Additionally, 4T1 cells 
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treated with IS and IR exosomes show an increase in BRD2 and BRD4 protein 
expression. We show that selective inhibition of BRD4 significantly decreases 4T1 cells 
migratory and invasive capacity induced by IR exosomes (Fig. 7). Thus, we show that 
BET proteins regulate breast cancer migration and invasion induced by adipocyte-derived 
exosomes. 
In order to investigate the role of exosomes in TME, we utilized the 4T1 cancer 
cell line to study the association of adipocyte-derived exosomes with the tumor cell 
invasion capacity and EMT. This syngeneic murine cell line can be used in a future 
mouse model, to study in vivo experiments to mimic the general scenario of metastatic 
breast cancer.  
 The molecular and morphological alterations of 4T1 cells exposed to adipocyte-
derived exosomes suggested a substantial degree of EMT of cancer cells in this model of 
TME. Recent studies propose that the aggressiveness of breast cancer is due in part to 
higher insulin concentration and higher IGF-1 level in patients with obesity. Yet many 
factors are simultaneously altered in obesity and metabolic disease that could drive breast 
cancer progression. We considered a role for adipocytes that have not previously been 
much studied: through crosstalk mediated by Evs. Our studies offer a novel approach to 
study EMT characteristics and the role of exosomes in the TME. However, exosomes 
have only relatively recently been identified as biologically important for cellular 
crosstalk, and our knowledge about exosomes is relatively limited, including the 
functional interaction of exosomes with recipient cells and the categorization of their 
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biological structure. Hence, exosomes should be analyzed and carefully quantified to 
create more in depth knowledge about cell-specific cargo.  
Earlier studies demonstrated that tumor-derived exosomes regulate E-cadherin 
and promote tumor progression. More recently, exosomal miRNAs in mesenchymal cells 
enhance EMT and associate with metastasis in lung cancer. As emerging evidence shows 
that IR adipocyte-derived exosomes alter transcriptional profiles of EMT markers, it 
suggests the association of IR adipocyte-derived exosomes with metastasis in breast 
cancer. This work focuses on exosomes from IR adipocytes, which play a surprising and 
critical role in cancer progression. Indeed, isolation of pure exosomes is a major 
challenge in the field and even today there is no agreement on a standard method. We 
have used exosome precipitation, which gives a high yield and is good for functional 
tests. Throughout the study, insulin-resistant exosomes significantly enhanced the 
migratory ability of cancer cells by regulating the EMT program and changing the BET 
protein profile of their recipient cells. It is worthwhile to study how to reverse the insulin 
resistance as well as EMT and BET protein alteration inside cancer cells. These data 
suggest that weight loss can diminish breast cancer incidence rates, which have been 
studied and proven by a large, multisite cohort study. It would be interesting to 
investigate whether patients who have undergone weight loss show different exosomal 
properties. On the other hand, increasing insulin sensitivity may also provide a solution to 
reverse the insulin-resistant status of adipocytes. Metformin, a first line diabetes 
medicine, may improve insulin sensitivity and may reduce the production and release of 
dangerous exosomes into the microenvironment.  
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It is noteworthy that adipocyte-derived exosomes changed BET protein 
expression of 4T1 cells. Several studies suggested that BET proteins also appear to play 
an important role in metabolic pathways and reprogram cancer cell metabolic activities. 
A pan-BET protein inhibitor, JQ1, has been shown to increase insulin secretion in 
pancreatic islet β-cells and also to stimulate fatty acid oxidation, which may enhance 
cancer cell migration, metastasis and drug resistance. On the other hand, selective 
knockdown of Brd2 and Brd4 suggested their independent roles as major BET regulators 
of distinct metabolic pathways in the β cells. Knockdown or inhibition of all BET 
proteins (Brd2, Brd3, and Brd4) may have undesirable and adverse effects for particular 
breast cancer patients. Our data show that a Brd4-selective degrader, MZ1, can 
downregulate migratory capacity of breast cancer cells. It is intriguing that selective BET 
protein inhibitors may be useful to reprogram insulin resistance status in adipocytes and 
become an adjuvant therapy in insulin resistance-related cancer.  
Our study focuses on the 4T1 cell line, which is derived from murine mammary 
carcinoma from BALB/c mouse. This cell line is suitable for in vivo and in vitro study, 
and is implantable into syngeneic BALB/c mice. The studies about metastatic disease in 
the exosome field, using mice, are still limited and challenging. Our study based on the 
4T1 syngeneic breast cancer cell line suggests the feasability of an in vivo study. By 
being a COMP carrier, insulin-resistant exosomes have shown their ability to enhance the 
aggressiveness of breast cancer cells even far away from the origin of the exosomes. A 
next step in the analysis might be to treat BALB/c mice with insulin-resistant exosomes 
and study its effects on breast cancer metastasis in mice. We previously addressed the 
 
29 
crucial role of IR exosomes in cancer development and progression in vitro. Results 
suggest that if we implant 4T1 breast cancer cells into BALB/c mice, we can reveal 
whether BALB/c mice treated with IR exosomes show augmented increase of metastasis 
and tumor aggressiveness in vivo. 
Overall, our findings provide important evidence and demonstrate the role of 
exosomes in crosstalk between cancer cells and adipocytes, especially IR adipocytes. Our 
results provide preliminary data for an in vitro study in a mouse model to be developed in 
the near future. Upon crosstalk with adipocytes, breast cancer cells can be energized to 
start metastatic progression and become more invasive and more aggressive in patients 
who have acquired insulin resistance syndrome. Intriguingly, we pointed out that breast 
cancer cells overexpressed Brd2 and Brd4 proteins, but Brd3. Specific targeting to knock 
down individual BET proteins is expected to control the metastatic disease, as our results 
suggest with MZ1, a Brd4-selective inhibitor. Additional studies are needed to develop a 
new epigenetic strategy involving specific BET protein transcriptional pathways for 
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